← Leaderboards
Shiaowen David Hsu
Duke University
$2,914,269
Attributed
$3,897,551
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $812.8K · FY2015–23$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,897,551 · 3
By mechanism
U01$3,108,051 · 1
R21$789,500 · 2
Top collaborators
- Xiling Shen3 shared
Most similar at Duke University
Same institution · by research overlap
- Jen-Tsan Ashley Chi$7,491,502
- Roger E McLendon$2,833,433
- Matthew Frank Kalady$1,849,540
- David Stephen Pisetsky$6,771,710
- G Greg Wang$11,565,583
Others in their field
Top investigators on “Phenotype”
- David R. Weir · University Of Michigan At Ann Arbor$239,033,262
- David Heimbrook · Leidos Biomedical Research, Inc.$213,586,034
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Richard A Gibbs · Baylor College Of Medicine$184,906,270
- James E. Gern · University Of Wisconsin-Madison$141,704,104
- Garret A Fitzgerald · University Of Pennsylvania$141,348,491
Research focus
PhenotypeResponseCellsFutureMolecularCancer CellPre-Clinical ModelTumorColorectal CancerBaseDrug ResistanceOrganoidsNeoplastic CellOxaliplatinPharmaceutical PreparationsIrinotecanImmunodeficient MouseMalignant NeoplasmsFluorouracilHeterogeneityEpigenomeInsightNeoplasm MetastasisCancer Model
Grant awards (9)
Microfluidic Droplet Organoids to Decipher the Tumor Heterogeneity in CRC of African Ancestry$221,286
R21 · FY2023 · CA · contact PI
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer$624,587
U01 · FY2022 · CA · contact PI
Microfluidic Droplet Organoids to Decipher the Tumor Heterogeneity in CRC of African Ancestry$188,169
R21 · FY2022 · CA · contact PI
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer$516,900
U01 · FY2021 · CA · contact PI
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer$644,430
U01 · FY2020 · CA
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer$683,864
U01 · FY2019 · CA
Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer$638,270
U01 · FY2018 · CA
Targeting Calreticulin in Colorectal Cancer Liver Metastasis$207,495
R21 · FY2016 · CA · contact PI
Targeting Calreticulin in Colorectal Cancer Liver Metastasis$172,550
R21 · FY2015 · CA · contact PI